"Microdosing" semaglutide typically means 0.1–0.5 mg weekly, well below the FDA-approved 0.25–2.4 mg escalation range; for tirzepatide it means 0.5–2.5 mg, below or at the lowest approved starting dose. Pharmacokinetics are roughly dose-proportional, making partial receptor occupancy and partial efficacy biologically plausible — but no large randomized trial has tested microdoses head-to-head against placebo. Most efficacy data is extrapolated from pivotal-trial dose-response curves and observational cohorts. This article walks through what the evidence does and does not establish, citing FDA labels and published trials directly.
GLP-1 microdosing refers to the off-label use of GLP-1 receptor agonists — most commonly semaglutide and tirzepatide — at weekly doses below the FDA-approved escalation range. The goal is partial appetite suppression or metabolic support with reduced GI side effects, not the maximum weight loss seen in pivotal trials.
The category emerged alongside the 2022–2024 obesity-medication boom. As compounded semaglutide and tirzepatide became widely accessible during FDA shortage declarations, users began experimenting below the 0.25 mg semaglutide and 2.5 mg tirzepatide starting points. There is no formal regulatory definition; the StatPearls semaglutide chapter (Shaefer et al., 2024) describes FDA dose ranges, and anything outside them is off-label.
In real-world practice, semaglutide microdoses span 0.1–0.5 mg weekly, with most users settling around 0.25 mg — the bottom of the FDA escalation. Tirzepatide microdoses range from 0.5 to 2.5 mg weekly. Anything below the lowest approved starting dose is fully off-label.
Per the FDA Ozempic prescribing information, semaglutide starts at 0.25 mg weekly for four weeks, then escalates to 0.5 and 1.0–2.0 mg (Ozempic) or 2.4 mg (Wegovy). Tirzepatide titrates from 2.5 to 15 mg. Liraglutide ranges 0.6–3.0 mg daily per the FDA Victoza/Saxenda label. Microdosing inverts the standard logic: rather than escalating to the dose that produced trial endpoints, the user stays at sub-maximal exposure indefinitely.
| Drug | Microdose range (off-label) | FDA-approved standard | Common rationale |
|---|---|---|---|
| Semaglutide | 0.1–0.5 mg weekly | 0.25–2.4 mg weekly | GI tolerability, maintenance after weight loss, metabolic support |
| Tirzepatide | 0.5–2.5 mg weekly | 2.5–15 mg weekly | Dual GIP/GLP-1 effect at sub-therapeutic dose, lower side effects |
| Liraglutide | 0.3–0.6 mg daily | 0.6–3.0 mg daily | Less common; rapid clearance limits microdose appeal |
Direct evidence at microdoses is sparse. The pivotal trials — STEP, SUSTAIN, SURMOUNT, SELECT — tested doses at or above FDA-approved escalation. STEP 1 used 2.4 mg semaglutide; SUSTAIN-6 used 0.5 and 1.0 mg; SURMOUNT-1 used tirzepatide 5, 10, and 15 mg; SELECT used semaglutide 2.4 mg. The 0.25 mg starting dose appears only as a transient titration step.
The closest signal toward sub-therapeutic efficacy comes from SUSTAIN-6, which included a 0.5 mg semaglutide arm. Marso et al. (NEJM 2016) reported significant cardiovascular event reduction in pooled 0.5 + 1.0 mg cohorts of T2D patients with high CV risk. The 0.5 mg arm sits at the upper edge of what is now called "microdosing" — evidence that 0.5 mg produced measurable benefit on a hard endpoint, though not in non-diabetic populations.
| Trial | Drug · Dose tested | Primary endpoint | Headline result |
|---|---|---|---|
| STEP 1 | Semaglutide 2.4 mg/wk | % body weight change at 68 wk | ~14.9% loss vs 2.4% placebo1 |
| SUSTAIN-6 | Semaglutide 0.5 + 1.0 mg/wk | First MACE in T2D + high CV risk | 26% relative MACE reduction2 |
| SURMOUNT-1 | Tirzepatide 5 / 10 / 15 mg/wk | % body weight change at 72 wk | ~15–21% loss, dose-dependent3 |
| SELECT | Semaglutide 2.4 mg/wk | MACE in obesity + established CVD | 20% relative MACE reduction4 |
The honest read: the lowest dose with hard-endpoint randomized data is 0.5 mg semaglutide weekly. Below that, claims rest on pharmacology — not trial results.
Both drugs exhibit roughly dose-proportional pharmacokinetics across their tested ranges. A 0.25 mg semaglutide dose produces approximately one-tenth the plasma exposure of a 2.4 mg dose, with the same ~7-day half-life. GLP-1 receptor occupancy follows a saturable binding curve, so partial occupancy at lower exposures is expected — and partial appetite, glycemic, and gastric-emptying effects are biologically plausible.
Per the FDA Ozempic label, semaglutide has 89% SC bioavailability, clearance ~0.05 L/h, and volume ~12.5 L. Tirzepatide shows similar dose-proportional behavior with ~80% bioavailability and a ~5-day half-life. What pharmacology does not tell you is the shape of the dose-response curve for clinical endpoints — receptor binding may be linear while weight loss or HbA1c reduction are non-linear. The partial-occupancy hypothesis is plausible but unproven below 0.5 mg semaglutide.
Reported benefits — drawn from clinician case series, observational cohorts, and pivotal-trial dose-response curves — fall into three buckets: smaller but meaningful weight loss (typically 3–7% over 6–12 months at semaglutide microdoses); markedly fewer GI side effects than at 1.0–2.4 mg; and gentler appetite suppression for long-term maintenance. None have been validated in head-to-head randomized microdose trials.
The GI tolerance claim is plausible because nausea, vomiting, and diarrhea are dose-dependent. SUSTAIN-6 reported nausea around 20% and vomiting around 10% at 0.5–1.0 mg; STEP 1 reported similar or higher rates at 2.4 mg. The 3–7% weight-loss figure is also plausible but unverified: titration weeks at 0.25 mg typically show 1–3% body-weight reduction within a month. Whether that compounds over 6–12 months at microdoses or plateaus quickly is not in randomized data.
Major unknowns: long-term efficacy below 0.25 mg semaglutide; weight regain trajectories versus standard doses; whether the 20% MACE reduction in SELECT extends to microdose or non-CVD populations; benefit versus structured lifestyle intervention; safety and potency of compounded preparations; and cost-effectiveness once compounded supply normalizes.
Risks are not zero just because doses are smaller. The boxed warning for thyroid C-cell tumors including medullary thyroid carcinoma applies across the dose range, per the Ozempic prescribing information. Pancreatitis, gallbladder disease, and retinopathy worsening are associated with GLP-1 therapy in FDA safety communications. The FDA has separately warned about events tied to compounded GLP-1 products. Provenance matters more at microdose levels because small absolute errors are larger percent-of-dose deviations.
GLP-1 microdosing is not FDA-approved. It is off-label use of FDA-approved drugs — or, often, off-label use of compounded versions that are not FDA-approved products at all. Off-label prescribing is legal in the U.S. but shifts the evidence burden onto prescriber and user.
The approved indications are narrow: Ozempic (semaglutide 0.25–2.0 mg weekly) for type 2 diabetes; Wegovy (semaglutide 2.4 mg) for chronic weight management in defined BMI categories; Mounjaro and Zepbound (tirzepatide 2.5–15 mg) for type 2 diabetes and chronic weight management respectively. Use at lower doses, in different populations, or with different goals falls outside that framing. The molecule is the same; the regulatory footing is not. The StatPearls semaglutide chapter summarizes approved indications in detail.
Dose Track logs and visualizes any semaglutide or tirzepatide protocol — standard escalation, custom titration, or off-label microdose maintenance — using FDA-derived pharmacokinetic parameters. Log a 0.1 mg semaglutide or 1.5 mg tirzepatide dose and the app projects plasma curves, weekly accumulation, steady-state, and decay after stopping. See GLP-1 tracking features, the medications list, or download Dose Track on the App Store.